1. Lan MS, Wasserfall C, Maclaren NK, Notkins AL (1996) IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 93:6367-6370 2. Saeki K, Zhu M, Kubosaki A et al. (2002) In the present study, IA-2 +/− mice (129/Sv x C57BL/6) were backcrossed to NOD/LtJ mice (Jackson Laboratory, Bar Harbor, Me., USA) for eight generations. IA-2 +/− NOD mice then were intercrossed to obtain IA-2 −/− NOD mice. All protocols were approved by our Institutional Animal Care and Use Committees. The IA-2 genotypes were determined by PCR using specific primers for the targeted locus and for the wild-type locus [2] . IA-2 protein expression in brain, analysed by Western blot, showed the presence of IA-2 in IA-2 +/+ NOD mice, but its absence in IA-2 −/− NOD mice (Fig. 1 ). IA-2 +/+ NOD and IA-2 − /− NOD mice then were injected with cyclophosphamide, a known accelerator of diabetes in NOD mice [5] . Animals were followed twice a week and mice with two consecutive nonfasting blood glucose determinations with values above 250 mg/dl were scored as diabetic. As seen in Fig. 1 , 44.4% of IA-2 +/+ NOD and 36.4% of IA-2 −/− NOD mice developed diabetes. Histologic examination of pancreatic islets from these animals showed insulitis. The number of IA-2 −/− NOD mice in our colony is still small, but five mice between 20 and 40 weeks of age already have developed diabetes spontaneously. Recently, we succeeded in knocking out IA-2β, a protein closely related to IA-2, and its role in the development of diabetes in NOD mice is currently under investigation.
The knockout studies described here show that IA-2 is not required for the development of diabetes in NOD mice and earlier knockout studies showed that glutamic acid decarboxylase 65 (GAD65) also is not required for the development of diabetes in NOD mice [6] . Although there is some evidence in NOD mice that these antigens could be involved in a cell-mediated immune response [7] , little if any autoantibodies are made to IA-2 or GAD65 in NOD mice [8] . In contrast to NOD mice, close to 90% of newly diagnosed patients with Type 1 Fig. 1 . Development of diabetes in IA-2 −/− NOD mice. Eightweek-old IA-2 +/+ NOD (■, n=18) and IA-2 −/− NOD (❏, n=22) female mice were treated (arrows) with cyclophosphamide We examined ghrelin concentrations in 22 children; 11 boys and 11 girls, age 16±3.6 years (mean±SD), BMI 18.0± 5.2 kg/m 2 (mean±SD) with a new onset of Type 1 diabetes. Blood samples were obtained at diagnosis before and after 10 days of insulin treatment, blood glucose 24.6±8.7 and 6.6± 3.0 mmol/l, respectively, and in conjunction with meal tests, carried out in 15 and 20 of the cases at 3 and 9 months after the start of insulin therapy, respectively. At meal tests the patients were fasting over night and had received no insulin in the morning. Then they had a standardised breakfast (20% of their daily energy intake, containing 33% fat, 50% carbohydrates and 17% proteins) and blood was drawn at time zero and after 30, 60, 90, 120, and 150 min. Ghrelin was measured in the samples taken just before the test and when C-peptide reached its maximum. Ghrelin was determined in serum using a radioimmunoassay (Phoenix Pharmaceuticals, Belmont, Calif., USA), which uses 125 I-labelled bioactive ghrelin as a tracer and a polyclonal antibody raised in rabbits against the fulllength, octanoylated human ghrelin. Intra-assay and inter-assay coefficients of variance were 5.3% and 13.6%, respectively. Statistical significance was evaluated by Mann-Whitney U test and Wilcoxon signed rank test. The study was approved by the Research Ethics Committee at the Faculty of Health Sciences, Linköping.
Ghrelin concentrations at diagnosis prior to insulin treatment and after 10 days were 48.9 ±24.6 and 74.3±61.5 pmol/l (mean±SD), respectively (p=0.007). Blood glucose and C-peptide values increased during the meal tests (Fig. 1) , whereas no changes in serum ghrelin were observed; the ghrelin values before and after test meals were 61.9±43.9 and 59.1±32.2 pmol/l at 3 months, and 93.4±72.4 and 81.9±55.5 pmol/l at 9 months, respectively. In a group of ten healthy children, five boys and five girls with a mean age of 12 years, the fasting serum ghrelin concentration was 108.5±32.5 pmol/l, (p=0.001), compared with the ghrelin values of the patients prior to insulin treatment.
To our knowledge, there are no previous reports on circulating ghrelin concentrations in patients with Type 1 diabetes. Patients with Type 2 diabetes were included in a previous study [6] which examined ghrelin concentrations in lean, normal weight and obese non-diabetic subjects and included observations on 42 subjects with Type 2 diabetes, 8 of whom were treated with diet alone, 22 with oral hypoglycaemic agents and 8 with insulin. Fasting plasma ghrelin concentration was negatively correlated with BMI in both subjects with Type 2 diabetes and those without. The plasma ghrelin concentrations of normal subjects decreased significantly after oral glucose administration, and a similar response was observed in patients with Type 2 diabetes after a meal tolerance test, reaching a nadir of 69% of the basal level after the meal. Similarly, a suppressive effect of a mixed liquid meal or oral glucose on serum ghrelin values in healthy human subjects was noted [8] . In contrast, we found that the children with Type 1 diabetes did not respond to meal tests with suppression of ghrelin values. One could speculate that ghrelin concentrations are low at di- Response to meal tests, carried out at 3 (n=15) and 9 (n=20) months after starting insulin treatment in childhood Type 1 diabetes. Results (mean ± SEM) from pre-and postmeal blood samples at each time point; ***p<0.0001; NS, nonsignificant
